Clinical Cancer Research CR Surrogrates Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Youssef, E. M.
Right arrow Articles by Lotan, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Youssef, E. M.
Right arrow Articles by Lotan, R.
Clinical Cancer Research Vol. 10, 1733-1742, March 2004
© 2004 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Hypermethylation of the Retinoic Acid Receptor2 Gene in Head and Neck Carcinogenesis

Emile M. Youssef1, Dafna Lotan1, Jean-Pierre Issa2, Kenichi Wakasa5, You-Hong Fan1, Li Mao1, Khaled Hassan1, Lei Feng3, J. Jack Lee3, Scott M. Lippman4, Waun K. Hong1 and Reuben Lotan1

Departments of 1 Thoracic/Head and Neck Medical Oncology, 2 Leukemia, 3 Biostatistics, and 4 Clinical Cancer Prevention, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas, and 5 Department of Pathology, Osaka City University Medical School, Osaka, Japan

Purpose: Retinoic acid receptor-ß2 (RAR-ß2) expression is suppressed in oral premalignant lesions and head and neck squamous cell carcinomas (HNSCCs). This study was conducted to determine whether RAR-ß2 gene expression in such lesions can be silenced by promoter methylation.

Experimental Design: RAR-ß2 methylation was analyzed in DNA samples from 22 pairs of primary HNSCC and adjacent normal epithelium, 124 samples of oral leukoplakia, and 18 HNSCC cell lines using methylation-specific PCR. RAR-ß2 promoter was methylated in 67, 56, and 53% of HNSCC tumors, HNSCC cell lines, and microdissected oral leukoplakia specimens, respectively. RAR-ß2 hypermethylation was confirmed by sodium bisulfite-PCR combined with restriction enzyme digestion analysis and by random cloning and sequencing of bisulfite-treated DNA isolates.

Results: Significantly higher RAR-ß2 hypermethylation levels were found in tumor tissue compared with adjacent normal tissue (P = 0.002). RAR-ß2 methylation in the cell lines was correlated with loss of RAR-ß2 expression (P = 0.013) and inversely related to the presence of mutated p53 (P = 0.025). The demethylating agent 5-aza-2'-deoxycytidine (5-aza-CdR) restored RAR-ß2 inducibility by all-trans-retinoic acid (ATRA) in some of the cell lines, which posses a methylated RAR-ß2 promoter. In some cell lines, this effect was associated with increased growth inhibition after combined treatment with 5-aza-CdR and ATRA.

Conclusions: RAR-ß2 silencing by methylation is an early event in head and neck carcinogenesis; 5-Aza-CdR can restore RAR-ß2 inducibility by ATRA in most cell lines, and the combination of 5-aza-CdR and ATRA is more effective in growth inhibition than single agents.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
E.-S. Lee, J.-P. Issa, D. B. Roberts, M. D. Williams, R. S. Weber, M. S. Kies, and A. K. El-Naggar
Quantitative Promoter Hypermethylation Analysis of Cancer-Related Genes in Salivary Gland Carcinomas: Comparison with Methylation-Specific PCR Technique and Clinical Significance
Clin. Cancer Res., May 1, 2008; 14(9): 2664 - 2672.
[Abstract] [Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
R. J. Shaw, G. L. Hall, D. Lowe, T. Liloglou, J. K. Field, P. Sloan, and J. M. Risk
The Role of Pyrosequencing in Head and Neck Cancer Epigenetics: Correlation of Quantitative Methylation Data With Gene Expression
Arch Otolaryngol Head Neck Surg, March 1, 2008; 134(3): 251 - 256.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. L. Carvalho, C. Jeronimo, M. M. Kim, R. Henrique, Z. Zhang, M. O. Hoque, S. Chang, M. Brait, C. S. Nayak, W.-W. Jiang, et al.
Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis Tool for Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., January 1, 2008; 14(1): 97 - 107.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
M. Xing
BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications
Endocr. Rev., December 1, 2007; 28(7): 742 - 762.
[Abstract] [Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
K. Chen, R. Sawhney, M. Khan, M. S. Benninger, Z. Hou, S. Sethi, J. K. Stephen, and M. J. Worsham
Methylation of Multiple Genes as Diagnostic and Therapeutic Markers in Primary Head and Neck Squamous Cell Carcinoma
Arch Otolaryngol Head Neck Surg, November 1, 2007; 133(11): 1131 - 1138.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Chen, H. Zhang, J. Lee, X. Liang, X. Wu, T. Zhu, P.-k. Lo, X. Zhang, and S. Sukumar
HOXA5 Acts Directly Downstream of Retinoic Acid Receptor {beta} and Contributes to Retinoic Acid Induced Apoptosis and Growth Inhibition
Cancer Res., September 1, 2007; 67(17): 8007 - 8013.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. D. Williams, N. Chakravarti, M. S. Kies, S.-I. Maruya, J. N. Myers, J. C. Haviland, R. S. Weber, R. Lotan, and A. K. El-Naggar
Implications of Methylation Patterns of Cancer Genes in Salivary Gland Tumors
Clin. Cancer Res., December 15, 2006; 12(24): 7353 - 7358.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
A. Rodriguez, C. Diez, S. Ikeda, L.J. Royo, J.N. Caamano, C. Alonso-Montes, F. Goyache, I. Alvarez, N. Facal, and E. Gomez
Retinoids during the in vitro transition from bovine morula to blastocyst
Hum. Reprod., August 1, 2006; 21(8): 2149 - 2157.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. Mori, S. J. O'Day, N. Umetani, S. R. Martinez, M. Kitago, K. Koyanagi, C. Kuo, T.-L. Takeshima, R. Milford, H.-J. Wang, et al.
Predictive Utility of Circulating Methylated DNA in Serum of Melanoma Patients Receiving Biochemotherapy
J. Clin. Oncol., December 20, 2005; 23(36): 9351 - 9358.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
W. J. Petty, N. Li, A. Biddle, R. Bounds, C. Nitkin, Y. Ma, K. H. Dragnev, S. J. Freemantle, and E. Dmitrovsky
A Novel Retinoic Acid Receptor {beta} Isoform and Retinoid Resistance in Lung Carcinogenesis
J Natl Cancer Inst, November 16, 2005; 97(22): 1645 - 1651.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. R. Hirsch and S. M. Lippman
Advances in the Biology of Lung Cancer Chemoprevention
J. Clin. Oncol., May 10, 2005; 23(14): 3186 - 3197.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
G. R. Bean, V. Scott, L. Yee, B. Ratliff-Daniel, M. M. Troch, P. Seo, M. L. Bowie, P. K. Marcom, J. Slade, B. F. Kimler, et al.
Retinoic Acid Receptor-{beta}2 Promoter Methylation in Random Periareolar Fine Needle Aspiration
Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 790 - 798.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. M. Lippman, J. Sudbo, and W. K. Hong
Oral Cancer Prevention and the Evolution of Molecular-Targeted Drug Development
J. Clin. Oncol., January 10, 2005; 23(2): 346 - 356.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
W. Qiu, B. Zhou, H. Zou, X. Liu, P. G. Chu, R. Lopez, J. Shih, C. Chung, and Y. Yen
Hypermethylation of Growth Arrest DNA Damage-Inducible Gene 45 {beta} Promoter in Human Hepatocellular Carcinoma
Am. J. Pathol., November 1, 2004; 165(5): 1689 - 1699.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Lotan and Y. Lotan
Retinoic Acid Receptor {beta}2 Hypermethylation: Implications for Prostate Cancer Detection, Prevention, and Therapy
Clin. Cancer Res., June 15, 2004; 10(12): 3935 - 3936.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.